{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.527","value":"78.15"},{"groupId":"OG001","spread":"18.661","value":"76.68"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"115"},{"groupId":"OG001","value":"143"}],"units":"Participants"}],"title":"Baseline: With mPFS event"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.648","value":"79.85"},{"groupId":"OG001","spread":"16.218","value":"79.91"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"533"},{"groupId":"OG001","value":"508"}],"units":"Participants"}],"title":"Without mPFS event"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.434","value":"2.68"},{"groupId":"OG001","spread":"17.848","value":"8.58"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"112"}],"units":"Participants"}],"title":"Change at end of treatment: with mPFS event"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.417","value":"3.35"},{"groupId":"OG001","spread":"16.141","value":"6.08"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"475"},{"groupId":"OG001","value":"452"}],"units":"Participants"}],"title":"Change at end of treatment: without mPFS event"}],"denoms":[{"counts":[{"groupId":"OG000","value":"664"},{"groupId":"OG001","value":"670"}],"units":"Participants"}],"description":"EORTC QLQ-C30 included 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and global health status/QOL scale. It has 28 questions (4-point scale where 1=not at all \\[best\\] to 4=Very Much \\[worst\\]) and 2 questions (7-point scale where 1=very poor \\[worst\\] to 7= excellent \\[best\\]). Raw scores were converted into scale scores from 0 to 100. For functional scales and global health status/QOL scale, higher scores show better QOL; for symptom scales, lower scores show better QOL. mPFS was time from date of randomization to date of first of documentation of PD, death due to any cause, or for participants who were confirmed non complete responders per IRF, receipt of subsequent anticancer therapy for HL after completion of frontline therapy. PD is any new lesion or increase by \\>=50% of previously involved sites from nadir.","dispersionType":"Standard Deviation","groups":[{"description":"Brentuximab vedotin 1.2 milligram per kilogram (mg/kg), infusion, intravenously over 30-minutes plus doxorubicin 25 milligram per square meter (mg/m\\^2), vinblastine 6 mg/m\\^2, and dacarbazine 375 mg/m\\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles. Brentuximab vedotin was administered within approximately 1 hour after completion of AVD.","id":"OG000","title":"A+AVD"},{"description":"Doxorubicin 25 mg/m\\^2, bleomycin 10 units per square meter (units/m\\^2), vinblastine 6 mg/m\\^2, and dacarbazine 375 mg/m\\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles.","id":"OG001","title":"ABVD"}],"paramType":"MEAN","populationDescription":"The ITT population included all participants randomized to treatment.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of treatment (approximately 1 year)","title":"Change From Baseline in Patient-Reported Outcome (PRO) Scores by mPFS Based on European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-C30 (EORTC QLQ-C30) at EOT","type":"SECONDARY","unitOfMeasure":"units on scale"}